EMMC Cancer Care, located at the Lafayette Family Cancer Center (Brewer, Maine), is the newest member of the Dana-Farber Cancer Care Collaborative. Participation in the Collaborative reflects a demonstrated commitment to excellence by meeting a wide array of standards and best practices.
Researchers led by scientists at Dana-Farber Cancer Institute say they have identified unique genomic changes that may be integral to testicular cancer development and explain why the great majority are highly curable with chemotherapy – unlike most solid tumors.
Researchers leading the largest genomic tumor profiling effort of its kind say such studies are technically feasible in a broad population of adult and pediatric patients with many different types of cancer.
An experimental kidney cancer drug outperformed the standard first-line therapy for patients with metastatic disease who are considered at risk for poorer than average outcomes, according to results of a randomized phase II clinical trial by researchers at Dana-Farber Cancer Institute.
New nursing leader named at Dana-Farber Cancer Institute. Anne Gross to start in new role on December 1, 2016.
Dana-Farber Cancer Institute investigators report they have discovered a type of immune antibody that can rapidly evolve to neutralize a wide array of influenza virus strains – including those the body hasn’t yet encountered.
William G. Kaelin, MD, professor in the Department of Medicine at Dana-Farber Cancer Institute and Harvard Medical School, has been named a winner of the 2016 Lasker Award for medical science by the Albert and Mary Lasker Foundation.
Men with testicular cancer who were uninsured or on Medicaid had a higher risk of death from what is normally a curable disease than insured patients, a new study by Dana-Farber Cancer Institute researchers found.
Dana-Farber/Brigham and Women’s Cancer Center has been named the best for cancer care in New England for the 16th straight year, and fourth overall in the country by U.S. News & World Report.
Dana-Farber Cancer Institute study published in the New England Journal of Medicine suggests that using repeated doses of an immunotherapy drug can restore a complete remission for some relapsed stem cell transplant recipients.
Stamford Hospital is first Connecticut hospital to join Dana-Farber/Brigham and Women's Cancer Care Collaborative
Investigators at Dana-Farber Cancer Institute in collaboration with scientists at the University of California, Berkeley, have identified a natural molecular pathway that enables cells to burn off calories as heat rather than store them as fat. This raises the possibility of a new approach to treating and preventing obesity, diabetes, and other obesity-linked metabolic disorders including cancer.
Researchers find cytoreductive nephrectomy may offer an overall survival benefit to patients with metastatic kidney cancer who are treated with targeted therapies
A crowd-sourcing strategy aimed at accelerating research into metastatic breast cancer has registered more than 2,000 patients from all 50 states in its first seven months, report researchers from Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard at the American Society of Clinical Oncology Annual Meeting.
The Albert Schweitzer Fellowship (ASF) announced its selections for the 2016 SPARK! Awards. Edward J. Benz, Jr., MD, President and CEO of Dana-Farber Cancer Institute, will receive the 2016 Schweitzer Clarion Award for Health Promotion and Education
Select studies Dana-Farber Cancer Institute researchers are presenting at the meeting
MatchMiner, an open computational platform developed at Dana-Farber Cancer Institute for matching patient-specific genomic profiles to precision cancer medicine clinical trials, has been named the winner of the Precision Trials Challenge at Harvard Business School.
Basic research into the dual nature of certain immune system cells has set the stage for a new approach to cancer immunotherapy that avoids some of the shortcomings associated with other methods, scientists at Dana-Farber Cancer Institute report in a new study.
Colorectal cancers heavily bedecked with tumor-related proteins called neoantigens are likely to be permeated with disease-fighting white blood cells, researchers at Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard report in a new study.
A simple blood test can rapidly and accurately detect mutations in two key genes in non-small cell lung tumors, researchers at Dana-Farber Cancer Institute and other institutions report in a new study – demonstrating the test’s potential as a clinical tool for identifying patients who can benefit from drugs targeting those mutations.
The Knight Cancer Institute at Oregon Health & Science University and Intel Corporation are expanding participation in the Collaborative Cancer Cloud, a distributed precision medicine analytics platform, to include Dana-Farber Cancer Institute and Ontario Institute for Cancer Research.
Scott A. Armstrong, MD, PhD, an internationally renowned pediatric hematologist/oncologist, has been named Chair of the Department of Pediatric Oncology at the Dana-Farber Cancer Institute, and the David G. Nathan Professor of Pediatrics at the Dana-Farber Cancer Institute, Boston Children’s Hospital, and Harvard Medical School.
Dana-Farber Cancer Institute researchers are leading a multicenter genetic study of prostate cancer in Sub-Saharan Africa to try to find new information about the genetic etiology of prostate cancer.
If you’re a lung or colorectal cancer patient, what’s in your wallet could determine your level of suffering and quality of life during treatment, according to a new study by Dana Farber Cancer Institute researchers.
An overwhelming majority of people with incurable cancer want to hear findings from DNA sequencing of their own tumors and normal cells, and to learn how those results may affect their health and treatment options, Dana Farber Cancer Institute scientists report.
Laurie H. Glimcher, MD, an internationally recognized immunologist, has been named the next president and CEO of Dana-Farber Cancer Institute, the Board of Trustees announced today.
Dana-Farber Cancer Institute and the EDI Institute are partnering to provide a new mobile imaging technique for cancer patients, family members, and staff to express their feelings around the illness. Expressive Digital Imagery (EDI) is used on a smartphone or tablet to provide a creative outlet for people to express complex feelings and emotions that words alone cannot.
How well a flu shot protects you from the virus can depend on your ethnic background and other inherited factors, report Dana-Farber Cancer Institute scientists.
In a first large-scale systematic study, researchers at Dana-Farber Cancer Institute, University of California, San Diego School of Medicine, and McGill University found that most sibling proteins – known as “protein isoforms” encoded by the same gene – often play radically different roles within tissues and cells, however alike they may be structurally.
An immuno-oncology collaboration with potential applicability in a wide range of oncology indications
Researchers found a way of differentiating angiocentric gliomas from other low-grade pediatric brain tumors and developed a pathological test that will help children avoid unnecessary and potentially damaging additional therapies.
Three Dana-Farber Cancer Institute researchers, writing in a special issue of JAMA published today, make the case for policies and practices that give terminally ill patients more control over how and where they will die
Backed by a growing body of research, investigators at Dana-Farber Cancer Institute are calling for all hospitals to establish bereavement programs for families of deceased patients.
New research by Dana-Farber Cancer Institute scientists raises the prospect of cancer therapy that works by converting a tumor’s best friends in the immune system into its gravest enemies.
A new drug for renal cell carcinoma slowed the growth of advanced kidney cancer in patients who became resistant to the first-line therapies that had previously kept it in check, according to results from a clinical trial led by Dana-Farber Cancer Institute.
In its first clinical trial, a breakthrough antibody therapy produced at least partial remissions in a third of patients with multiple myeloma who had exhausted multiple prior treatments, investigators at Dana-Farber Cancer Institute and other organizations report.
Regular consumption of caffeinated coffee may help prevent the return of colon cancer after treatment and improve the chances of a cure, according to a new, large study from Dana-Farber Cancer Institute that reported this striking association for the first time.
Men with metastatic, hormone-sensitive prostate cancer gained more than a year of survival when they received both hormone-blocking medications and chemotherapy right after diagnosis, rather than delaying the chemo until the cancer worsened, according to a study led by Dana-Farber’s Christopher Sweeney published in the New England Journal of Medicine.
Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC), a leader in the field, has a new website to connect patients and physicians with information about precision cancer medicine.
A novel blood test could greatly improve triage of victims of radiation accidents by rapidly predicting who will survive, who will die, and who should receive immediate medical countermeasures, according to scientists at Dana-Farber Cancer Institute.
Research led by scientists at Dana-Farber Cancer Institute showed a new drug and a potentiating agent lengthened the lives of patients with metastatic colorectal cancer, all of whom had exhausted available standard treatments.
Men who went on cholesterol-lowering statin drugs when they began androgen deprivation therapy for prostate cancer had a longer time in which their disease was under control than did men who didn’t take statins, a clinical trial led by Dana-Farber Cancer Institute investigators shows.
Websites that market personalized cancer care services often overemphasize their purported benefits and downplay their limitations, and many sites offer genetic tests whose value for guiding cancer treatment has not been shown to be clinically useful, according to a new study from Dana-Farber Cancer Institute.
With March marking Colorectal Cancer Awareness Month, Dr. Jeffery Meyerhardt at Dana-Farber Cancer Institute, answers some key questions about the disease:
President Barack Obama is requesting an increase of $215 million in the 2016 federal budget to launch the Precision Medicine Initiative. This boost in funding for research will give genetic causes of cancer a national focus specifically around precision or “personalized” treatments for cancer in the future. Here are some facts about precision medicine.
Study by Dana-Farber Cancer Institute scientists indicates that the pool of patients who can benefit from the drug olaparib is potentially much wider – and offers a ready means of identifying them.
Dana-Farber Cancer Institute is expanding its research footprint, occupying portions of five floors at Longwood Center, 360 Longwood Avenue in Boston, MA, beginning later this month.
A new study by Dana-Farber Cancer Institute investigators demonstrates that vitamin D can protect some people with colorectal cancer by perking up the immune system’s vigilance against tumor cells.
According to a new study led by researchers at Dana-Farber Cancer Institute, clinical trial patients with metastatic colorectal cancer who had high levels of vitamin D in their bloodstream prior to treatment with chemotherapy and targeted drugs, survived longer, on average, than patients with lower levels of the vitamin. Those findings were reported today at the 2015 American Society of Cancer Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco.
Dana-Farber researchers report women with small, HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted drug following surgery were highly unlikely to have the cancer recur within three years.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right